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Identification of variant Alport phenotypes using an Alport-specific
antibody probe. An antibody, which recognizes an epitope(s) on a 26 kD
peptide of the noncollagenous domain of type IV collagen and which
fails to bind to basement membranes of individuals with Alport syn-
drome, was used to characterize members of families representing
phenotypic variants of the disorder. Ten of 11 families with juvenile-
onset renal failure and 4 of 5 families with adult-onset renal failure
exhibited loss of the epitope(s) from epidermal and/or renal basement
membranes by indirect immunofluorescence. Two families with typical
Alport nephropathy but normal hearing exhibited the same abnormal-
ity. This study provides strong evidence that a defect in the main
noncollagenous domain of type IV collagen is common to the various
phenotypes of Alport syndrome.
Alport syndrome (progressive hereditary nephntis) is a ge-
netically and phenotypically heterogeneous disorder. Results of
studies of multiple pedigrees indicate that the disease can be
transmitted as either an autosomal or an X-linked dominant trait
[1, 2], suggesting that defects involving at least two genetic loci
can result in the Alport phenotype. The age at which end-stage
renal disease (ESRD) or death occurs in affected males varies
considerably among families, although intrafamilial concor-
dance of age at death or ESRD is high [1, 3, 4]. Atkin, Gregory
and Border segregated Alport families into two groups: in one
the mean age of death or ESRD in affected males is less than 31
years, and in the other death or ESRD occurs later in life [5].
Another example of phenotypic heterogeneity is the absence of
sensorineural hearing loss in families otherwise indistinguish-
able clinically and pathologically from families with classical
Alport syndrome [6—8]. Atkin et al [5] have proposed six major
types of dominantly-inherited Alport syndrome (Table 1).
These variants of Alport syndrome have in common charac-
teristic ultrastnictural alterations of glomerular basement mem-
brane (GBM), consisting of thickening of the glomerular capil-
lary wall with fragmentation of the lamina densa of the GBM
into multiple interlacing strands [6, 9, 10]. Small electron-dense
granules are often found between strands of lamina densa.
When present diffusely these changes are diagnostic of Alport
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syndrome [11, 12], although focal lamina densa splitting can be
seen in a variety of glomerular disorders [13].
Another abnormality of GBM unique to patients with Alport
syndrome is loss of reactivity with anti-GBM antibodies derived
from patients with Goodpasture syndrome, first described by
Olson Ct a! and later confirmed by other investigators [14—16].
The absence of a normal antigenic component of GBM was
further suggested by reports of Alport patients who developed
anti-GBM nephritis in their renal allografts [15, 17]. Loss of
GBM reactivity with Goodpasture serum was also observed in
male dogs with Samoyed hereditary glomerulopathy, an animal
model of the Alport nephropathy [18].
Absence of the Goodpasture antigen is not universally found
in Alport patients [19]. Females in particular are likely to retain
Goodpasture reactivity, because the mutant X-linked gene is
inactivated in a portion of their GBM-producing cells [20].
However, normal staining of GBM using a monoclonal antibody
directed against the Goodpasture antigen was seen in some
males with Alport syndrome who satisfied histological criteria
for the diagnosis [21, 22].
In 1986 Kashtan et al [23] described a study of the transmis-
sion of the antigenic defect in basement membrane in four
families with Alport syndrome. The anti-basement membrane
serum was obtained from an Alport male who developed
anti-GBM nephritis in his HLA-identical renal allograft. IgG in
this serum reacted intensely with normal epidermal basement
membrane (EBM) as well as GBM, but failed to react with EBM
or GBM from eight Alport males. Affected females in these
families exhibited patchy loss of EBM reactivity with the
serum, as might be expected for a disorder transmitted in an
X-linked dominant fashion. Immunochemical studies revealed
that the antibody recognized an epitope(s) on a 26 kilodalton
(kD) monomer and related dimers of the main noncollagenous
(NCI) domain of type IV collagen. Subsequent immunochemi-
cal studies of GBM from male patients with Alport syndrome
demonstrated the absence of novel 28 kD chains related to type
IV collagen suggesting a close structural relationship between
the 26 and 28 kD components [24].
We now report results of studies in 24 families with Alport
syndrome, representing four of the six major phenotypic vari-
ants proposed by Atkin et al [5]. Loss of the reactive basement
membrane determinant in each of the X.linked dominant vari-
ants, suggests that this alteration is not associated with a
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Table 1. Six phenotypes of dominantly inherited Alport syndrome [5]
Age at Deaf-




II X-linked Juvenile Yes Ocular
III X-linked Adult Yes None
IV X-linked Adult No None
V Autosomal ?d Yes Macrothrombo-
cytopenia
VI Autosomal Juvenile Yes Ocular
a Juvenile-type nephritis is characterized by intrakindred mean age of
ESRD <31 years in affected males versus >31 years in adult type.
b An interim category of juvenile-type nephritis with deafness for
kindreds in which affected males have had no offspring. Linkage
analysis should eventually make it possible to segregate these families
into types H and VI.
C Also known as Epstein syndrome (hereditary nephritis, deafness
and macrothrombocytopenia) [44].d Assignment not possible on basis of currently available data.
particular Alport variant, and that the defect involves the NCI
domain of type IV collagen.
Methods
Families and controls
Skin specimens (3 to 5 mm in diameter) were obtained by
punch biopsy from the volar aspect of the forearm of 64
members of 24 families with Alport syndrome. Kidney biopsy
specimens only were studied from individuals in kindreds SC
and KA. The diagnosis of Alport syndrome was made when any
three of the following five criteria were satisfied: (a) the finding
of hematuria in multiple members of a family; (b) progression to
renal failure in at least one male kindred member; (C) the
presence of progressive sensorineural hearing loss in males with
renal disease; (d) the presence of anterior lenticonus in an
individual with renal disease; and (e) the finding, in at least one
affected male in a kindred, of diffuse thickening of the glomer-
ular basement membrane (GBM) associated with the "basket-
weave" transformation of the lamina densa characteristic of
Alport syndrome [6—9], along with negative direct immunoflu-
orescence. A single family (family WE) satisfying only two
criteria was included because renal biopsy of an affected male
was diagnostic of Alport syndrome. Each family exhibited a
dominant inheritance pattern, except for families McD, KA and
TI in which only a single male could be demonstrated to have
the disease. In family BE three siblings are affected but neither
parent has evidence of disease; the parents are not consanguin-
eous.
Families EV, MA, PE, HO, and MU were subjects of
previous studies at the University of Minnesota [16, 23].
Families PB, P, M, C and 3 were described in a report from the
University of Utah [41. Family N/A was first reported as family
W in the study of Chazan et al [25].
The families were categorized using the classification system
proposed by Atkin and associates (Table 1) [5]. Eight families
were classified as having type I Alport syndrome. In these
families the disease is inherited as a dominant trait and the mean
age at onset of ESRD in affected males is less than 31 years of
age. Because affected males in these families have had no
offspring, differentiation between X-linked and autosomal in-
heritance has not been possible. Families PB and BS were
tentatively designated as having type II disease. Families N/A,
D/S, KR, P, FL and MU have adult-type nephritis with deaf-
ness, or type III Alport syndrome. Families 3 and C have type
IV disease. We did not study any families with type V Alport
syndrome, in which hereditary nephritis and deafness are
associated with macrothrombocytopenia, or any families with
juvenile type, autosomal dominantly-transmitted (type VI) Al-
port syndrome.
Several families were not classifiable using this scheme. In
families McD, KG and TI only a single male was apparently
affected. Each of the males had ultrastructural abnormalities of
GBM characteristic of Alport syndrome, and the affected
individual in family McD had anterior lenticonus as well. These
individuals may represent new mutations [26] or they may be
offspring of asymptomatic carriers [27]. In families HO and WE
there was no family history of ESRD, and the affected males
were adolescents with mild renal insufficiency. Family WI
exhibited autosomal dominant transmission of nephritis and
sensorineural deafness, with the development of ESRD delayed
until adulthood. It should be noted that families apparently
similar to family WI have been described by other investigators
[I].
Controls consisted of five specimens of skin obtained from
normal volunteers, and eight histologically and immunohisto-
chemically normal specimens collected from individuals under-
going clinical evaluation of various disorders. The protocol for
collection and study of skin specimens from patients, family
members and controls was approved by the Committees on the
Use of Human Subjects in Research of the Universities of
Minnesota and Utah.
Alport antibody probe
The anti-basement membrane antibody probe used in this
study has been previously described [23, 28, 29]. The antibody
was present in serum and an eluate from the renal allograft of a
patient with Alport syndrome who developed severe anti-GBM
antibody-mediated glomerulonephritis in each of two renal
allografts. The patient received his first renal allograft at age 20;
anti-GBM nephritis developed one month after transplantation.
Anti-GBM nephritis of a renal allograft from a cadaver donor
developed within three months of retransplantation at age 23. In
each instance, light microscopy of the allograft revealed a
severe crescentic glomerulonephritis, accompanied by linear
deposition of IgG, IgA and C3 on GBM and some tubular
basement membranes by direct immunofluorescence. Both al-
lografts were eventually lost despite plasmapharesis and cyto-
toxic therapy. Pre-plasmapharesis serum obtained after the first
transplant was used in our earlier studies [23]. More recently we
have used an eluate derived from the patient's second allograft,
using 0.02 M citrate, pH 3.2 [16]. The serum and eluate were
indistinguishable when used to stain tissues or Western blots of
collagenase-digested GBM [23]. These are referred to collec-
tively as "Alport anti-GBM probe." By Western blot analysis
the antibody reacts with a 26 kD monomer and related dimers of
the NCI domain of type IV collagen and does not bind to neutral
or cationic 28 kD chains which are principal target antigens of
Goodpasture antibodies [23, 29, 30].
By immunofluorescence both the serum and eluate stain
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Table 2. CharacteristiCs of families and results of indirect immunofluorescence using the Alport antibody probe
Immunofluorescence of basement membranesa
Normal
Family L Bx HL FH ESRD
Affected males
No. result
Affected females Normal males




EV + + + + + I neg (s,k) I mosaic
MA + + + + 4 neg (s,k) I mosaic I pos
PE + + + + 2 neg (s,k) 3 2 pos, I mosaic 4 pos
SE + + + + 1 neg (s) I pos
BE + + + + I neg(s)
MIT + + + 1 neg (s) 2 1 pos, 1 mosaic
SC + + + + 1 neg(k)
KA + + + I neg(k)
M + + + + 1 pos(s)
Type II
PB + + + + I neg(s)
BS + + + + 2 neg (s,k) I mosaic
Type 111
N/A + + + 3 neg (s) 4 mosaic I 05 I pos
KR + + + + 2 mosaic (s,k)
P + + + + I neg(s)
FL + + + + I neg (s) I pos
MU + + + + 2 05 (s) I pos
Type IV
3 + + + 1 neg (s) I mosaic
C + + + 2 neg (s) 3 I neg, 2 mosaic
Indeterminate
WI + + + 1 pos(s)
MCD + + + + I 05 (s,k)
KG + + + I pos(s)
HO + + + I neg (s,k) 2 mosaic
WE + + I pos (s) I 05 I 05
TI + + + I neg(s,k)
Abbreviations are: L, anterior lenticonus; Bx, renal biopsy diagnostic of Alport syndrome; HL, sensorineural hearing loss; FH, multiple family
members with hematuria; ESRD, end-stage renal disease.
a The presence (pos) or absence (neg) of basement membrane reactivity with the Alport antibody probe is indicated. Skin(S) and kidney (K) were
studied in 8 families, skin alone in 14, and kidney alone in 2.
GBM, Bowman's capsule and distal tubular basement mem-
branes in sections of normal human kidney, and the epidermal
basement membrane (dermal-epidermal junction) of normal
human skin. Staining of both normal kidney and skin is en-
hanced by pretreatment of tissue sections with acid-urea, but
the distribution of staining is not changed [23].
Indirect immunohistologic studies of skin and kidney were
carried out as previously described [23].
Results
Results of indirect immunofluorescence studies of EBM
(GBM in families SC and KA) are presented in Table 2.
Examples of the negative and mosaic patterns of staining are
presented in Figure 1. We felt that examining one male in a
family was sufficient to characterize it as displaying positive or
negative reactivity because our original studies [23] had indi-
cated that the presence or absence of reactivity was not affected
by age in affected males and that all affected males studied
within a particular family had identical EBM reactivity with the
probe.
Ten of 11 type I Alport families displayed absence of EBM or
GBM reactivity with the anti-GBM probe. At this time we
cannot with certainty discriminate X-linked (type II) or autoso-
mal dominant (type VI) inheritance in any of these families. The
predominance among affected females in these kindreds of mild
renal involvement associated with a mosaic pattern of EBM
reactivity is suggestive of X-linked dominant inheritance. Fur-
ther categorization of at least some of these families will be
possible with linkage analysis.
Both families tentatively assigned to the type H category also
showed a negative staining reaction with the probe. It is likely
that some, if not all, of the families classified as having type I
disease in fact carry a mutation in an X-chromosomal gene and
therefore have type II Alport syndrome.
Four of the five type III families exhibited loss of the EBM
epitope. These families are thus immunohistochemically indis-
tinguishable from those in types I and II. In the fifth family, two
affected males, one of whom has undergone kidney transplan-
tation, and one affected female showed normal staining of EBM
with the probe. Renal biopsies were performed in three of the
affected males in this family, prior to the availability of electron
microscopy. Light microscopic features were consistent with a
diagnosis of Alport syndrome.
The EBM of three affected males in the two families with type
IV disease completely lacked reactivity with the probe (Figure
1). Affected women in these two families showed either a
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Fig. 1. Immunofluorescence photomicrographs of skin biopsy specimens from Iwo members offamily 3, a kindred with type IV Alport syndrome.
The sections were denatured in acid-urea and stained with the Alport anti-GBM probe followed by fluorescein isothiocyanate-conjugated rabbit
lgG, as described in Methods. In A, there is no binding of the Alport anti-GBM probe to the epidermal basement membrane (EBM) of an affected
male (X 175). His affected sister's skin is shown in B. Note the mosaic pattern of reactivity, with areas of normal binding adjacent to nonreactive
regions of EBM (X 175). E: epidermis; D: dermis; arrows: EBM.
mosaic pattern or complete absence of reactivity. Thus these
type IV families were indistinguishable from types I, II and III
families using this methodology.
Five families could not be classified using the present scheme
with respect to the pattern of inheritance or the age at onset of
death/ESRD and were therefore placed in the "indeterminate"
group. In one of these families (HO) the EBM of an affected
male failed to react with the probe and two affected females
exhibited a mosaic pattern. The single affected male in family TI
also had nonreactive EBM. Members of the remaining four
kindreds showed normal reactivity.
Discussion
While a number of investigators have documented the unique
alterations of antigenic composition of Alport GBM [14—16,
20—23], to our knowledge this is the first description of the
association of antigen loss with specific Alport variants. Be-
cause our antibody probe allows the differentiation of Alport
and non-Alport tissues on the basis of reactivity with the EBM
in skin we were able to include families that might otherwise be
inaccessible to this type of study. Other anti-GBM antibodies
synthesized by Alport patients following renal transplantation
that have no reactivity with normal epidermal basement mem-
branes have been described [31]. However, we have recently
observed an anti-GBM serum from a second Alport patient that
stains epidermal basement membranes of normal individuals
but not Alport epidermal basement membranes (unpublished
observations). Like the anti-GBM antibody used in the present
report, this second anti-GBM serum reacts with a 26 kD
monomer and related dimers of the NCI domain of type IV
collagen by Western blot analysis.
Our first notable finding was that the loss of the basement
membrane antigen recognized by our probe was not associated
with a particular Alport phenotype. That is, families with
adult-type nephritis (that is, types III and IV disease) were as
likely to exhibit loss of the antigen as families with juvenile-type
nephritis (that is, types I and II). Our data demonstrate that at
least some families with Alport nephropathy in the absence of
deafness also lack this basement membrane component. This
finding suggests that a specific abnormality in basement mem-
brane composition is shared by families with types I, II, III, and
IV Alport syndrome. The factors underlying the different rates
of progression of nephropathy in the juvenile and adult variants
as well as the reason for the preservation of hearing in type IV
disease remain to be elucidated.
Four of the six families we were unable to classify exhibited
preservation of the epitope recognized by our antibody probe.
We are reluctant to attach any significance to this finding, since
the families in this group appear to represent several variants of
hereditary nephritis. For instance, family HO most likely has an
X-linked dominant disorder, while nephropathy and deafness
are transmitted as autosomal dominant traits in family WI. At
this time we can offer only speculative explanations for the
preservation of basement membrane antigenicity in some fam-
ilies with typical ultrastructural lesions of GBM (family M in the
type I group, family MU with type III disease, and families KG
and WE in the indeterminate group). We suspect that the
genetic defect in these families results in a dysfunctional
basement membrane protein without altering the relevant
epitope. Alternatively, a mutant gene at a separate locus could
result in basement membrane structural and functional defects
similar to those of Alport syndrome, with preservation of the
epitope.
Our inclusion of families lacking sensorineural hearing loss in
a study of Alport syndrome would perhaps be disputed by
investigators who feel that such an approach, at least given our
current level of understanding of hereditary nephritis, is more
confusing than enlightening [32, 33]. However, thorough inves-
tigation of these families reveals similarities to families with
classical hereditary nephritis that seem too compelling to dis-
count. For example, the ultrastructural lesion of GBM may be
indistinguishable from that deemed specific for Alport syn-
drome [6, 7], as described in members of family C with type IV
disease [8]. Furthermore, the intrakindred mean age of ESRD
among affected males in family P (type III disease) and in two
families with type IV disease (including family 3) were essen-
tially identical [4], supporting the contention that the glomerular
basement membrane lesion is similar in the two groups. Finally,
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Atkin et al have mapped both type III and type IV disease to the
same region of the long arm of the X chromosome, suggesting
that these variants may arise from allelic mutations at a single
genetic locus [34]. To this morphological and genetic evidence
we can now add immunohistochemical evidence in support of
the contention that some families with hereditary nephritis and
normal hearing have a nephropathy identical to that occurring
in families with "classic" Alport syndrome, that likely arises
from a mutation at the same genetic locus. We believe that
families with hereditary nephritis in the absence of sensonneu-
ral hearing loss may legitimately be considered to have a variant
of Alport syndrome when the typical ultrastructural or antigenic
alterations of basement membranes are present.
Preservation of hearing in families with type IV Alport
syndrome may result from a defect in the gene product of the
Alport locus that compromises the structural integrity of the
GBM but does not interfere with the function of cochlear
basement membranes, at least to a degree that is clinically
apparent. It is also possible that deletion of contiguous genes
results in hereditary nephritis and deafness in some families,
while only a gene affecting GBM structure is affected in families
with the nephropathy alone. Further molecular genetic studies
will be required to clarify these issues.
Families of different putative types (PE of type I, P and N/A
of type III, 3 and C of type IV) have been included in studies of
the linkage of the Alport gene to polymorphic loci on the X
chromosome [34, 35]. The disease gene in each of these families
has been mapped to the middle of the long arm of the X
chromosome (Xq2l .3-q22). As noted above, these linkage re-
sults are consistent with the notion that types III and IV
represent allelic mutations occurring at a single genetic locus.
The antigenic abnormality shared by these variants may reflect
an alteration in the primary amino acid sequence of a protein, or
a change in the activity of an intermediary protein such as a
modifying enzyme. In either case, the gene product affected is
likely to be the same in types III and IV Alport syndrome.
Linkage studies of families with type II disease, as well as
families like M and MU that do not fit the general pattern of
antigen loss (see table II), are currently in progress.
Our previous work has identified the peptide recognized by
our antibody probe as most probably a component of the main
noncollagenous (NCI) domain of type IV collagen [23], the
predominant collagenous component of basement membranes.
The 26 kilodalton collagenase-resistant peptide targeted by this
antibody on Western blots appears to be derived from the
alpha1(IV) chain of type IV collagen, although this has not been
shown with absolute certainty [36, 371. It is possible that this
particular 26 kD component represents a genetically distinct
collagen chain that co-purifies with the alpha1(IV) NCI domain.
The results of the present study, as well as the results of our
linkage analyses, indicate that families identified by the Alport
anti-GBM probe display X-linked dominant inheritance of the
disease. If the 26 kD peptide targeted by the probe is in fact
derived from the alpha(IV) chain, it is unlikely that the Alport
mutation involves the amino acid sequence of the alpha1(IV)
chain, since the gene for this polypeptide, like the gene for the
alpha2(IV) chain, has been mapped to the distal long arm of
chromosome 13 [38—43]. In that case it would be more likely
that the conformation of the alpha1(IV) NCI domain is altered
post-translationally in Alport basement membranes. These al-
ternative possibilities are the subject of current investigations,
as is the structural relationship between the 26 kD and 28 kD
noncollagenous peptides in normal and Alport GBM.
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